Kvistgård, Denmark, March 18, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced
today that the company, in accordance with a board decision of today, introduces
a three year incentive programme in April for all employees in the Bavarian
Nordic Group. The programme is a cash bonus programme based on so-called phantom
shares (bonus programme based on the company's shares). This means that each
employee in the programme will be entitled to exercise a number of phantom
shares when the programme expires in 2013 and, thus, receive a cash bonus
calculated from the increase in the company's share price. The incentive
programme will not have dilutive effect on existing shares.
With effect from 1 April 2010 every month each employee is awarded up to three
phantom shares per month of employment until 31 March 2013 and can during the
term of the programme receive a maximum of 108 phantom shares. New employees
employed after commencement of the programme will participate in the programme
after 3 months employment. The exercise price is DKK 248 and has been
established as the average share price ("closing price") for the Company's share
in a period of 15 business days prior to 18 March 2010 added a 15 % premium.
However, the exercise price is as minimum established as the average trading
price of the Company's shares today. At the time of exercise each employee in
the programme will receive a cash bonus per phantom share equivalent to DKK 1
per share point the company's share price exceeds the exercise price. The cash
bonus is subject to taxation.
The exercise period is a two week period starting the day after the company's
release of its quarterly report for first quarter in 2013. Exercise of phantom
shares is subject to the company's share price exceeding the exercise price by
at least 10 per cent at the time of exercise in 2013.
Based on the current number of employees in the company, this 3 year incentive
programme will comprise up to 38,880 phantom shares, of which the CEO &
President will receive up to 108 phantom shares and members of executive
management will receive up to 648 phantom shares. The average value of each
phantom share equals DKK 44 calculated on the basis of the Black-Scholes model
with a risk-free interest rate of 2.0 per cent and on the historical volatility
of the shares. The calculation is based on a market value of the share of DKK
238 per share.
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; biodefence, cancer and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for
advanced prostate cancer is being developed under a collaboration agreement with
the National Cancer Institute.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
<http://www.bavarian-nordic.com/>
[HUG#1395486]
